The upcoming GST council meeting is likely to provide relief on a slew of cancer drugs, sources with knowledge of the matter told CNBC-TV18.

Sources further said that the GST council nominated fitment committee is likely to reduce GST on cancer drugs like Trastuzumab Deruxtecan, Osimertinib, Durvalumab to 5% from the current levels of 12%.

The Fitment committee recommendations are based on proposals shared by the Health ministry to make cancer treatment affordable in the company.

Abbott India, Zydus Life, Alkem Laboratories, Reliance Lifesciences, Cipla, Mylan, Biocon are the manufacturers of these drugs in India.

The GST council is set to meet on September 9 in New Delhi.